GLP-1 Market
LLY $1382.75 ▼ -2.3% NVO $39.43 ▼ -3.1% PFE $28.06 ▼ -1.4% VKTX $26.17 ▼ -2.6% KLRA $11.79 ▼ -3.4% GPCR $17.36 ▼ -4.5% RHHBY $59.52 ▼ -1.2%
Market data delayed up to 20 min · Source: Twelve Data
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Ranolazine

Company
Swathy Chandrashekhar, MBBS
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
4 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

4 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Nov 19, 2026

Find a Clinical Trial Near Me

See recruiting studies for Ranolazine and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT04606459

    COSIMA: COronary SInus Reducer for the Treatment of Refractory Microvascular Angina

    Not yet reported Johannes Gutenberg University Mainz 144 participants Est. completion 2029-10-20 1 site
    Other conditions: Coronary Microvascular Disease, Refractory Angina
    View official trial listing →
  • Recruiting NCT NCT06527222

    A Study of Ranolazine in ALS

    Not yet reported Swathy Chandrashekhar, MBBS 72 participants Est. completion 2028-07 6 sites Stand-alone
    Other conditions: Amyotrophic Lateral Sclerosis
    View official trial listing →
  • Recruiting NCT NCT06570473

    Feasibility Trial for a Right Ventricular Failure Platform Trial

    Not yet reported University of Alberta 30 participants Est. completion 2027-06 5 sites Stand-alone
    Heart failure Other conditions: Pulmonary Hypertension, Right Ventricular Dysfunction
    View official trial listing →
  • Recruiting NCT NCT07380919

    Inhibition of Late Sodium Current (INa) to Prevent Coronary MICROvascular Dysfunction in Patients Presenting With ST-Elevation Myocardial Infarction and Multivessel Disease: INaMICRON Study

    Not yet reported, Not yet reported Federico II University 100 participants Est. completion 2026-06 3 sites Stand-alone
    Other conditions: STEMI (ST Elevation MI)
    View official trial listing →
  • Completed NCT NCT00091429

    Ranolazine SR in Patients With Chronic Angina Who Remain Symptomatic Despite Maximal Treatment With Amlodipine

    Not yet reported Gilead Sciences 500 participants Est. completion 2005-02
    Other conditions: Angina
    View official trial listing →
  • Completed NCT NCT00099788

    Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes

    Not yet reported Gilead Sciences 6560 participants Est. completion 2007-02 1 site Stand-alone
    Other conditions: Myocardial Ischemia
    View official trial listing →
  • Completed NCT NCT00570089

    Microvascular Coronary Disease In Women: Impact Of Ranolazine

    Not yet reported Cedars-Sinai Medical Center 20 participants Est. completion 2009-12 1 site Stand-alone
    Other conditions: Myocardial Ischemia
    View official trial listing →
  • Terminated NCT NCT00574756

    Effect of Ranolazine on Echocardiographic Indices of Diastolic Dysfunction

    Not yet reported University of California, San Diego 14 participants Est. completion 2010-03 1 site
    Heart failure Other conditions: Ranolazine, Tissue Doppler Ultrasound, Echocardiography
    View official trial listing →
  • Completed NCT NCT00644332

    An Open-label, Multi-center Study Evaluating the Validity, Reliability, and Responsiveness of a New Female-specific Angina Questionnaire in Women With Chronic Angina Treated With Ranolazine Extended-release Tablets (CVT 3041)

    Not yet reported Gilead Sciences 172 participants Est. completion 2011-01 29 sites
    Other conditions: Chronic Angina
    View official trial listing →
  • Withdrawn NCT NCT00657514

    Ranolazine Versus Placebo Effects on Exercise Tolerance in Patients With Heart Disease and Peripheral Arterial Disease

    Not yet reported Colorado Prevention Center Est. completion 2009-06 3 sites
    Other conditions: Peripheral Arterial Disease, Angina
    View official trial listing →
  • Terminated NCT NCT00832572

    Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneuropathy

    Not yet reported Gilead Sciences 5 participants Est. completion 2009-06 1 site Stand-alone
    Cardiovascular disease Other conditions: Pain, Peripheral Nervous System Diseases, Polyneuropathy
    View official trial listing →
  • Terminated NCT NCT00914316

    Supervised Treadmill Exercise and Ranolazine for Intermittent Claudication of Lower Extremities

    Not yet reported Corewell Health East 29 participants Est. completion 2013-03 1 site
    Other conditions: Peripheral Arterial Disease
    View official trial listing →
  • Completed NCT NCT00998218

    Effect of Ranolazine on Arrhythmias and Microvolt T- Wave Alternans (MVTWA) Patients With LV Dysfunction

    Not yet reported Aspirus Heart and Vascular Institute-Research and Education 7 participants Est. completion 2010-12 1 site Stand-alone
    Substance use disorder Other conditions: Ventricular Arrythmias
    View official trial listing →
  • Completed NCT NCT01163721

    Exploratory Study to Access the Metabolic Effects of Ranolazine in Subjects With Type 2 Diabetes Mellitus When Added to Ongoing Non-insulin Antidiabetic Therapy

    Not yet reported Gilead Sciences 80 participants Est. completion 2010-11 9 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01163734

    Ranolazine in Diastolic Heart Failure

    Not yet reported Gilead Sciences 20 participants Est. completion 2011-02 1 site Stand-alone
    Heart failure
    View official trial listing →
  • Completed NCT NCT01174173

    Ranolazine and Pulmonary Hypertension

    Not yet reported Northwestern University 11 participants Est. completion 2014-10 1 site Stand-alone
    Other conditions: Angina, Pulmonary Arterial Hypertension
    View official trial listing →
  • Completed NCT NCT01215253

    Ranolazine Implantable Cardioverter-Defibrillator Trial

    Not yet reported University of Rochester 1012 participants Est. completion 2017-02-28 90 sites
    Heart failure Other conditions: Ischemic Cardiomyopathy, Nonischemic Cardiomyopathy
    View official trial listing →
  • Completed NCT NCT01221272

    Effect of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging

    Not yet reported Gilead Sciences 81 participants Est. completion 2012-09 43 sites Stand-alone
    Other conditions: Myocardial Perfusion Imaging, Myocardial Ischemia
    View official trial listing →
  • Status unknown NCT NCT01304095

    Ranolazine, Ethnicity and the Metabolic Syndrome

    Not yet reported Atlanta Heart Specialists, LLC 160 participants Est. completion 2013-11 2 sites
    Cardiovascular diseaseMetabolic syndrome Other conditions: Angina
    View official trial listing →
  • Withdrawn NCT NCT01334203

    A Study on the Effects of Ranolazine on Exercise Duration in Subjects With Chronic Stable Angina and Coronary Artery Disease (CAD) With Type 2 Diabetes Mellitus (T2DM)

    Not yet reported Gilead Sciences Est. completion 2012-12 Stand-alone
    Cardiovascular diseaseType 2 diabetes Other conditions: Angina Pectoris
    View official trial listing →
  • Completed NCT NCT01342029

    Treatment With Ranolazine in Microvascular Coronary Dysfunction (MCD): Impact on Angina Myocardial Ischemia

    Not yet reported Cedars-Sinai Medical Center 142 participants Est. completion 2016-12 2 sites Stand-alone
    Other conditions: Microvascular Coronary Dysfunction (MCD)
    View official trial listing →
  • Completed NCT NCT01345188

    Ranolazine in Ischemic Cardiomyopathy

    Not yet reported Midwest Cardiovascular Research Foundation 28 participants Est. completion 2014-04 1 site
    Other conditions: Cardiomyopathy, Chest Pain, Dyspnea
    View official trial listing →
  • Terminated NCT NCT01349491

    Ranolazine for the Prevention of Atrial Fibrillation After Electrical Cardioversion

    Not yet reported University of Oklahoma 10 participants Est. completion 2014-06 2 sites Stand-alone
    Other conditions: Atrial Fibrillation
    View official trial listing →
  • Terminated NCT NCT01352416

    Suppression Of Atrial Fibrillation With Ranolazine After Cardiac Surgery

    Not yet reported Corewell Health East 15 participants Est. completion 2012-11 2 sites
    Other conditions: Heart; Dysfunction Postoperative, Cardiac Surgery
    View official trial listing →
  • Completed NCT NCT01425359

    Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina

    Not yet reported Gilead Sciences 949 participants Est. completion 2012-10 135 sites Stand-alone
    Cardiovascular diseaseType 2 diabetes Other conditions: Angina Pectoris
    View official trial listing →
  • Completed NCT NCT01435174

    Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients

    Not yet reported University of Michigan 17 participants Est. completion 2013-03 1 site Stand-alone
    Cardiovascular disease Other conditions: End-stage Renal Disease
    View official trial listing →
  • Completed NCT NCT01442038

    Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)

    Not yet reported Gilead Sciences 2651 participants Est. completion 2015-02 218 sites Stand-alone
    Cardiovascular disease Other conditions: Angina Pectoris
    View official trial listing →
  • Completed NCT NCT01472185

    Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus

    Not yet reported Gilead Sciences 465 participants Est. completion 2013-10 159 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01480336

    The Adjunctive Ventricular Arrhythmia Suppression Trial (AVAST) Pilot

    Not yet reported Hartford Hospital 19 participants Est. completion 2013-01 1 site
    Other conditions: Arrhythmia
    View official trial listing →
  • Status unknown NCT NCT01490255

    Pharmacodynamic Effects of Ranolazine Versus Amlodipine on Platelet Reactivity

    Not yet reported University of Roma La Sapienza 100 participants Est. completion 2014-06 2 sites
    Cardiovascular disease
    View official trial listing →
  • Status unknown NCT NCT01491061

    Ranolazine Loading to Prevent PCI-induced Myocardial Injury

    Not yet reported University of Roma La Sapienza 100 participants Est. completion 2017-12 1 site
    Cardiovascular disease
    View official trial listing →
  • Completed NCT NCT01494987

    Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

    Not yet reported Gilead Sciences 431 participants Est. completion 2013-08 140 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT01495520

    Ranolazine for Improving Symptoms of Palpitations

    Not yet reported University of Roma La Sapienza 100 participants Est. completion 2016-12
    Other conditions: Ischemic Heart Disease
    View official trial listing →
  • Completed NCT NCT01505179

    The Effects of Ranolazine on Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction

    Not yet reported University of California, San Diego 10 participants Est. completion 2015-01 1 site
    Heart failure
    View official trial listing →
  • Completed NCT NCT01522651

    Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation

    Not yet reported Gilead Sciences 134 participants Est. completion 2014-03-10 50 sites Stand-alone
    Other conditions: Atrial Fibrillation
    View official trial listing →
  • Completed NCT NCT01534962

    Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion

    Not yet reported Menarini Group 241 participants Est. completion 2014-03 4 sites Stand-alone
    Other conditions: Persistent Atrial Fibrillation
    View official trial listing →
  • Completed NCT NCT01546558

    Single Cohort, 2-Period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine 500 mg

    Not yet reported Gilead Sciences 25 participants Est. completion 2012-03 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01546597

    Single Cohort 4-period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine

    Not yet reported Gilead Sciences 24 participants Est. completion 2012-03 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01555164

    A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone

    Not yet reported Gilead Sciences 442 participants Est. completion 2013-10 146 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT01558830

    Safety of Amiodarone and Ranolazine Together in Patients With Angina

    Not yet reported Cardiovascular Consultants of Nevada 50 participants Est. completion 2013-07 3 sites
    Cardiovascular disease Other conditions: Chronic Stable Angina, Atrial Fibrillation, Ventricular Tachycardia
    View official trial listing →
  • Terminated NCT NCT01562041

    Evaluation of Exercise Treadmill Test (ETT) Indices in Participants With Cardiovascular Disease

    Not yet reported Novartis Pharmaceuticals 14 participants Est. completion 2014-01-02 2 sites Stand-alone
    Other conditions: Atherosclerotic Coronary Vascular Disease
    View official trial listing →
  • Terminated NCT NCT01590979

    Randomized Double Blind Control Trial on Effects of Ranolazine on New Onset Atrial Fibrillation

    Not yet reported Northwell Health 54 participants Est. completion 2015-06 1 site
    Other conditions: Atrial Fibrillation New Onset, Hemorrhage, Prolonged QTc Interval, Ventricular Tachycardia, Medical Care; Complications, Late Effect of Complications
    View official trial listing →
  • Completed NCT NCT01648205

    Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients

    Not yet reported University of Rochester 25 participants Est. completion 2018-07-20 1 site Stand-alone
    Other conditions: Long QT Syndrome
    View official trial listing →
  • Terminated NCT NCT01675973

    A Phase 1 Study to Assess the Effect of Severe Renal Impairment on the Pharmacokinetics, as Well as Safety/Tolerability, of Ranolazine

    Not yet reported Gilead Sciences 4 participants Est. completion 2012-08 1 site Stand-alone
    Other conditions: Severe Renal Impairment
    View official trial listing →
  • Completed NCT NCT01703156

    Low Risk Acute Coronary Syndrome

    Not yet reported University of Oklahoma 70 participants Est. completion 2012-07 1 site Stand-alone
    Other conditions: Low Risk Acute Coronary Syndrome
    View official trial listing →
  • Terminated NCT NCT01705509

    The Effects of Ranolazine on CPET Parameters in Ischemic Cardiomyopathy Patients (ERIC)

    Not yet reported Cardiovascular Institute of the South Clinical Research Corporation 14 participants Est. completion 2017-03-31 1 site
    Other conditions: Cardiomyopathy
    View official trial listing →
  • Completed NCT NCT01721967

    Ranolazine for the Treatment of Chest Pain in HCM Patients

    Not yet reported Duke University 14 participants Est. completion 2016-05 1 site Stand-alone
    Other conditions: Hypertrophic Cardiomyopathy
    View official trial listing →
  • Status unknown NCT NCT01728025

    Long Term Prophylactic Therapy of Congenital Long QT Syndrome Type III (LQT3) With Ranolazine

    Not yet reported Tel-Aviv Sourasky Medical Center 10 participants Est. completion 2017-11 1 site Stand-alone
    Other conditions: Long QT Syndrome Type 3
    View official trial listing →
  • Completed NCT NCT01754259

    Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Diabetic Patients and CAD

    Not yet reported Brigham and Women's Hospital 47 participants Est. completion 2015-12 1 site Stand-alone
    Cardiovascular disease Other conditions: Diabetes, Type I, Diabetes, Type II, Angina
    View official trial listing →
  • Completed NCT NCT01757808

    A Study of Ranolazine Acute Administration and Short Term Administration in Pulmonary Arterial Hypertension

    Not yet reported University of Chicago 12 participants Est. completion 2015-01 1 site Stand-alone
    Other conditions: Pulmonary Arterial Hypertension
    View official trial listing →
  • Terminated NCT NCT01767987

    Ranolazine Cardioprotection in PCI

    Not yet reported Harvey Hahn 6 participants Est. completion 2014-04 1 site
    Other conditions: Acute Coronary Syndrome
    View official trial listing →
  • Completed NCT NCT01797484

    Reduction of Ischemic Myocardium With Ranolazine-Treatment in Patients With Acute Myocardial Ischemia

    Not yet reported, Not yet reported Universitätsklinikum Hamburg-Eppendorf 20 participants Est. completion 2015-06 1 site
    Cardiovascular disease Other conditions: Acute Myocardial Ischemia
    View official trial listing →
  • Status unknown NCT NCT01804543

    Impact of Ranolazine on Myocardial Ischemia Detected by High-Field 3T Cardiovascular Magnetic Resonance (CMR) Imaging and P-31 Spectroscopy

    Westside Medical Associates of Los Angeles 30 participants Est. completion 2014-12 1 site
    Other conditions: Angina, Heart Disease
    View official trial listing →
  • Status unknown NCT NCT01810796

    Pathophysiology and Prevention of Perioperative Myocardial Injury: A Prospective Randomized Controlled Trial

    Not yet reported Hadassah Medical Organization 300 participants Est. completion 2017-12 1 site Stand-alone
    Cardiovascular disease
    View official trial listing →
  • Completed NCT NCT01815957

    Impact of Ranolazine on Coronary Microcirculatory Resistance

    Not yet reported University of New Mexico 7 participants Est. completion 2016-03 1 site Stand-alone
    Cardiovascular disease Other conditions: Coronary Microcirculation, Myocardial Disease, Ischemia
    View official trial listing →
  • Completed NCT NCT01839110

    Targeting the Right Ventricle in Pulmonary Hypertension

    Not yet reported University of Pennsylvania 22 participants Est. completion 2018-01 3 sites
    Other conditions: Pulmonary Hypertension
    View official trial listing →
  • Completed NCT NCT01843127

    A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.

    Not yet reported Gilead Sciences 24 participants Est. completion 2013-09 3 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01873950

    Study of the Electrocardiographic Effects of Ranolazine, Dofetilide, Verapamil, and Quinidine in Healthy Subjects

    Not yet reported Food and Drug Administration (FDA) 22 participants Est. completion 2014-12 Stand-alone
    Other conditions: Drug-induced Surface ECG Changes
    View official trial listing →
  • Terminated NCT NCT01887353

    The Use of Ranolazine for Atrial Fibrillation and Diastolic Heart Failure

    Not yet reported Intermountain Health Care, Inc. 8 participants Est. completion 2014-02 1 site
    Heart failure Other conditions: Atrial Fibrillation
    View official trial listing →
  • Completed NCT NCT01917136

    11C-acetate/18Fluorodeoxyglucose-FDG PET/CT and Cardiac MRI in Pulmonary Hypertension

    Not yet reported University of Pennsylvania 21 participants Est. completion 2018-10 1 site
    Other conditions: Pulmonary Hypertension
    View official trial listing →
  • Completed NCT NCT01948310

    Effects of Ranolazine and Exercise on Daily Physical Activity Trial

    Not yet reported Duke University 38 participants Est. completion 2016-10-10 1 site
    Other conditions: Chronic Stable Angina
    View official trial listing →
  • Status unknown NCT NCT01979965

    Effect of Ranolazine on Valvular Disease in Patients With Pacemakers

    Not yet reported University Cardiology 50 participants Est. completion 2014-09 1 site
    Other conditions: Ischemic Mitral Regurgitation
    View official trial listing →
  • Completed NCT NCT01992016

    A Pilot Study to Enhance F18 FDG-PET Imaging of Prostate Cancers With the Metabolic Inhibitor Ranolazine

    Not yet reported University of Colorado, Denver 11 participants Est. completion 2018-04-11 1 site Stand-alone
    Other conditions: Adenocarcinoma of the Prostate, Bone Metastases, Soft Tissue Metastases, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
    View official trial listing →
  • Status unknown NCT NCT01996618

    Study to Reduce Symptoms of Premature Beats With Ranolazine

    Not yet reported Walter Reed National Military Medical Center 72 participants Est. completion 2016-07 1 site Stand-alone
    Other conditions: Premature Ventricular Beats
    View official trial listing →
  • Completed NCT NCT02052011

    Ranolazine and Microvascular Angina by PET in the Emergency Department

    Not yet reported Yale University 31 participants Est. completion 2015-11 1 site Stand-alone
    Other conditions: Microvascular Angina
    View official trial listing →
  • Completed NCT NCT02133352

    Study of Ranolazine in the Treatment of Pulmonary Hypertension Associated With Diastolic Left Ventricular Dysfunction

    Not yet reported Boston University 10 participants Est. completion 2014-05 1 site Stand-alone
    Other conditions: Pulmonary Hypertension, Diastolic Left Ventricular Dysfunction
    View official trial listing →
  • Completed NCT NCT02133911

    A Pilot Trial of Ranolazine to Treat Patients With Dilated Cardiomyopathy

    Not yet reported University Medical Centre Ljubljana 10 participants Est. completion 2016-04-02 1 site Stand-alone
    Other conditions: Dilated Cardiomyopathy
    View official trial listing →
  • Completed NCT NCT02147067

    Microvascular Assessment of Ranolazine in Non-Obstructive Atherosclerosis (MARINA)

    Not yet reported Emory University 26 participants Est. completion 2018-06 1 site Stand-alone
    Other conditions: Microvascular Angina
    View official trial listing →
  • Terminated NCT NCT02147834

    Effectiveness of Ranolazine on Reducing Chest Pain in Patients With Blockage But no Stents

    Not yet reported North Florida Foundation for Research and Education 5 participants Est. completion 2016-09 1 site
    Other conditions: Angina
    View official trial listing →
  • Terminated NCT NCT02156336

    Ranolazine for Diabetic Peripheral Neuropathic Pain (DPNP)

    Not yet reported Horizons International Peripheral Group 4 participants Est. completion 2017-02-08 3 sites
    Other conditions: Diabetic Peripheral Neuropathic Pain
    View official trial listing →
  • Terminated NCT NCT02239926

    Effect of Ranolazine on Gastrointestinal Motor Function and Pain in Patients With IBS-D

    Not yet reported, Not yet reported Mayo Clinic 5 participants Est. completion 2015-09 1 site
    Other conditions: Diarrhea Predominant Irritable Bowel Syndrome
    View official trial listing →
  • Completed NCT NCT02251457

    Study of Ranolazine in Myotonia Congenita, Paramyotonia Congenita and Myotonic Dystrophy Type 1

    Not yet reported Ohio State University 35 participants Est. completion 2017-12-18 1 site Stand-alone
    Other conditions: Myotonia Congenita, Paramyotonia Congenita, Myotonic Dystrophy 1
    View official trial listing →
  • Completed NCT NCT02252406

    Impact of Ranolazine in Blood Markers in Women With Angina and Metabolic Syndrome

    Not yet reported University of Florida 33 participants Est. completion 2019-05-17 1 site Stand-alone
    Metabolic syndrome Other conditions: Stable Angina
    View official trial listing →
  • Completed NCT NCT02265796

    Ranolazine Among Unrevascularized Chronic Stable Angina Patients

    Not yet reported North Florida Foundation for Research and Education 50 participants Est. completion 2016-09 1 site
    Other conditions: Angina
    View official trial listing →
  • Completed NCT NCT02360397

    Ranolazine Mediated PVC Reduction in Ischemic Heart Disease

    Not yet reported Kent Hospital, Rhode Island 6 participants Est. completion 2018-02-23 1 site Stand-alone
    Other conditions: Ventricular Premature Complexes, Myocardial Ischemia
    View official trial listing →
  • Withdrawn NCT NCT02423265

    Efficacy of Ranolazine in Patients With Chronic Total Occlusions of Coronary Arteries

    Not yet reported East Carolina University Est. completion 2017-03 1 site
    Cardiovascular disease Other conditions: Myocardial Ischemia, Arteriosclerosis, Chronic Stable Angina
    View official trial listing →
  • Completed NCT NCT02425969

    A Trial in Stable Intermediate Coronary Lesions and Grey-zone FFR Values

    Not yet reported Golden Jubilee National Hospital 108 participants Est. completion 2016-10-01 1 site Stand-alone
    Other conditions: Grey-zone Fractional Flow Reserve, Intermediate Coronary Lesions, Stable Angina, Coronary Physiology
    View official trial listing →
  • Withdrawn NCT NCT02611596

    Does Ranolazine Decrease Biomarkers of Myocardial Damage in Diabetics

    Not yet reported Walter Reed National Military Medical Center Est. completion 2019-11 Stand-alone
    Type 2 diabetes Other conditions: Silent Myocardial Ischemia
    View official trial listing →
  • Withdrawn NCT NCT02687269

    Ranolazine a Potential New Therapeutic Application

    Not yet reported Fondazione Policlinico Universitario Agostino Gemelli IRCCS Est. completion 2020-10 Stand-alone
    Other conditions: Myocardial Stunning
    View official trial listing →
  • Status unknown NCT NCT02817932

    A Study of Pharmacokinetics and Safety of Ranolazine PR in Healthy Korean and Caucasian Male Subjects

    Not yet reported A.Menarini Asia-Pacific Holdings Pte Ltd 120 participants Est. completion 2016-10 1 site Stand-alone
    Other conditions: Healthy Male Individuals
    View official trial listing →
  • Completed NCT NCT02829034

    Targeting Right Ventricle in Pulmonary Hypertension Gilead

    Not yet reported University of Pennsylvania 22 participants Est. completion 2018-01 3 sites
    Other conditions: Pulmonary Hypertension
    View official trial listing →
  • Status unknown NCT NCT03044964

    Effect of Ranolazine on Activity Level in Patients With Angina After FFR Based Deferred Intervention (REPTAR)

    Not yet reported Amit Malhotra, MD 40 participants Est. completion 2017-10 1 site
    Other conditions: Angina
    View official trial listing →
  • Completed NCT NCT03070470

    CiPA Phase 1 ECG Biomarker Validation Study

    Not yet reported Food and Drug Administration (FDA) 60 participants Est. completion 2017-06-26 1 site
    Other conditions: Drug-induced QT Prolongation, Pharmacokinetics, Pharmacodynamics
    View official trial listing →
  • Withdrawn NCT NCT03162120

    Comparison of Effectiveness of Ranolazine Plus Metoprolol Combination vs. FlecainidE pluS Metoprolol Combination in ATrial Fibrillation Recurrences FOllowing PhaRmacological or Electrical CardioverSion of AtRial Fibrillation

    Not yet reported, Not yet reported Elpen Pharmaceutical Co. Inc. Est. completion 2018-12-01
    Other conditions: Atrial Fibrillation, Recurrence
    View official trial listing →
  • Withdrawn NCT NCT03257683

    RANOLAZINE STUDY: Speckle Tracking Derived Myocardial Strain

    Saint Thomas Health Est. completion 2018-02-16 1 site
    Cardiovascular disease Other conditions: Ischaemic Myocardial Dysfunction
    View official trial listing →
  • Completed NCT NCT03401502

    A TSHRN1201 Sub-study-To Evaluate the Effects of add-on Ranolazine on Exercise Tolerance and Angina Frequency

    Not yet reported TSH Biopharm Corporation Limited 20 participants Est. completion 2019-03-31 1 site Stand-alone
    Other conditions: Angina
    View official trial listing →
  • Completed NCT NCT03472950

    Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis

    Not yet reported University of Kansas Medical Center 14 participants Est. completion 2022-12-09 1 site Stand-alone
    Other conditions: ALS
    View official trial listing →
  • Status unknown NCT NCT03486561

    Management of Ischemic Heart Disease With Angiwell-XR (Ranolazine)

    Not yet reported OBS Pakistan 2000 participants Est. completion 2018-10-31
    Other conditions: Chronic Stable Angina
    View official trial listing →
  • Completed NCT NCT03953989

    Effects of Ranolazine on Coronary Microvascular Dysfunction in Patients With Hypertrophic Cardiomyopathy

    Not yet reported IRCCS San Raffaele 26 participants Est. completion 2020-03-06 1 site Stand-alone
    Other conditions: HCM - Hypertrophic Non-Obstructive Cardiomyopathy
    View official trial listing →
  • Terminated NCT NCT04456517

    Reduce Crohn's-Associated Diarrhea With Sodium Channel Therapy

    Not yet reported Vanderbilt University Medical Center 4 participants Est. completion 2024-04-11 1 site Stand-alone
    Other conditions: Crohn's Disease, Inflammatory Bowel Disease
    View official trial listing →
  • Completed NCT NCT07054255

    Bioequivalence Study of Ranolazine Extended-release Tablets in Healthy Chinese Subjects

    Not yet reported Haisco Pharmaceutical Group Co., Ltd. 72 participants Est. completion 2020-12-21 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Ranolazine, Ranexa

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.